CA2836405C - Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale - Google Patents
Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale Download PDFInfo
- Publication number
- CA2836405C CA2836405C CA2836405A CA2836405A CA2836405C CA 2836405 C CA2836405 C CA 2836405C CA 2836405 A CA2836405 A CA 2836405A CA 2836405 A CA2836405 A CA 2836405A CA 2836405 C CA2836405 C CA 2836405C
- Authority
- CA
- Canada
- Prior art keywords
- testosterone
- gel
- testosterone gel
- intranasal
- intranasal testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Abstract
L'invention concerne des gels intranasaux de testostérone permettant une libération prolongée de testostérone dans la circulation systémique d'hommes et de femmes pour obtenir des taux sanguins efficaces constants de testostérone, sans induire de pic de testostérone non voulu dans les taux sanguins suite à l'administration pernasale. Les gels intranasaux de testostérone selon l'invention sont sans danger, pratiques à utiliser, bien tolérés, stables et peuvent être fabriqués facilement et reproductible à grande échelle. En outre, puisque les taux sanguins de testostérone supra-normaux et sous-normaux sont supposés être sensiblement maintenus à un minimum ou empêchés, et que les taux sériques de testostérone sont supposés rester sensiblement constants pendant la vie de la dose, c'est-à-dire que les gels intranasaux de testostérone selon l'invention permettent d'imiter les taux de testostérone physiologiques quotidiennement rythmiques normaux ou de restaurer les taux sanguins de testostérone à des taux de testostérone physiologiques quotidiennement rythmiques normaux, ces nouveaux gels conviennent, de manière unique, à une thérapie de remplacement de testostérone ou d'apport d'un complément de testostérone, et pour traiter efficacement des hommes chez qui on a diagnostiqué par exemple une déficience en testostérone, comme une faible libido sexuelle, un faible désir sexuel, une faible activité sexuelle, une faible fertilité, une faible spermatogenèse, une aspermatogenèse, une dépression et/ou un hypogonadisme, et des femmes chez qui on a diagnostiqué une dysfonction sexuelle, comme une faible libido sexuelle, un faible désir sexuel, une faible activité sexuelle, une faible réactivité du noyau amygdalien, une faible stimulation sexuelle, un trouble du désir sexuel hypo-actif (HSDD), un trouble de l'excitation sexuelle et/ou une anorgasmie. L'invention concerne également des méthodes et des applicateurs sans air multi-doses pré-remplis destinés à une administration pernasale des gels nasaux de testostérone selon l'invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3034552A CA3034552C (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486324P | 2011-05-15 | 2011-05-15 | |
| US61/486,324 | 2011-05-15 | ||
| US201161486634P | 2011-05-16 | 2011-05-16 | |
| US61/486,634 | 2011-05-16 | ||
| PCT/IB2012/001127 WO2012156822A1 (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testostérone à libération prolongée, méthodes associées et systèmes applicateurs multi-doses pré-remplis destinés à une administration pernasale |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034552A Division CA3034552C (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2836405A1 CA2836405A1 (fr) | 2012-11-22 |
| CA2836405C true CA2836405C (fr) | 2021-09-07 |
Family
ID=46579248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2836398A Active CA2836398C (fr) | 2011-05-15 | 2012-05-15 | Formulations intranasales bio-adhesives de gel de testosterone et leur utilisation pour traiter l'hypogonadisme chez les hommes |
| CA3034552A Active CA3034552C (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale |
| CA2836405A Active CA2836405C (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2836398A Active CA2836398C (fr) | 2011-05-15 | 2012-05-15 | Formulations intranasales bio-adhesives de gel de testosterone et leur utilisation pour traiter l'hypogonadisme chez les hommes |
| CA3034552A Active CA3034552C (fr) | 2011-05-15 | 2012-05-15 | Gels nasaux de testosterone a liberation prolongee, methodes associees et systemes applicateurs multi-doses pre-remplis destines a une administration pernasale |
Country Status (16)
| Country | Link |
|---|---|
| EP (3) | EP2709588B1 (fr) |
| JP (9) | JP6152092B2 (fr) |
| KR (9) | KR20200028503A (fr) |
| CN (4) | CN110613679A (fr) |
| AR (2) | AR086409A1 (fr) |
| AU (11) | AU2012257492A1 (fr) |
| BR (2) | BR112013029332A2 (fr) |
| CA (3) | CA2836398C (fr) |
| DK (1) | DK2714006T3 (fr) |
| EA (1) | EA201391701A1 (fr) |
| ES (1) | ES2859784T3 (fr) |
| IL (2) | IL229401A0 (fr) |
| MX (4) | MX2020008599A (fr) |
| PL (1) | PL2714006T4 (fr) |
| WO (2) | WO2012156822A1 (fr) |
| ZA (2) | ZA201309264B (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| EP2709588B1 (fr) * | 2011-05-15 | 2021-08-25 | Acerus Biopharma Inc. | Gels nasaux de testostérone à libération prolongée, méthodes associées et systèmes applicateurs multi-doses pré-remplis destinés à une administration pernasale |
| US8971800B2 (en) * | 2011-05-31 | 2015-03-03 | Qualcomm Incorporated | Methods and apparatus for improving NFC activation and data exchange reporting mechanisms |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014076569A2 (fr) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Formulations de testostérone topiques à libération commandée et procédés associés |
| WO2014093818A2 (fr) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Utilisation d'une nouvelle technique sous-cutanée sans aiguille pour administrer de la testostérone chez des hommes souffrant d'hypogonadisme |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| ES2749588T3 (es) * | 2013-10-07 | 2020-03-23 | Antares Pharma Inc | Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja |
| EP3107547A4 (fr) | 2014-02-19 | 2017-11-15 | Antares Pharma, Inc. | Administration de compositions de testostérone par injection par jet assistée par aiguille |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| CA2951284A1 (fr) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Creme transdermique |
| WO2016123317A1 (fr) * | 2015-01-28 | 2016-08-04 | Prometheon Pharma, Llc | Formulations topiques à base de facteurs de croissance |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
| BR122023025444A2 (pt) * | 2016-01-07 | 2024-02-20 | Viramal Limited | Composição de gel estável, e, método de preparação de uma composição em gel estável |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| EP3448466A1 (fr) | 2016-04-25 | 2019-03-06 | Koska Family Ltd. | Système d'administration de médicament |
| MX2018014978A (es) * | 2016-06-02 | 2019-09-04 | Acerus Labs Inc | Composiciones nasales de cannabidiol. |
| MX2018014906A (es) * | 2016-06-03 | 2019-08-21 | M et P Pharma AG | Composiciones farmaceuticas nasales con un excipiente poroso. |
| HUE063346T2 (hu) * | 2017-01-20 | 2024-01-28 | M et P Pharma AG | Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére |
| KR102164230B1 (ko) | 2017-06-17 | 2020-10-12 | 엘지전자 주식회사 | 무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치 |
| US11234928B2 (en) * | 2017-11-27 | 2022-02-01 | Aska Pharmaceutical Co., Ltd. | Powder preparation for nasal administration |
| CA3090262A1 (fr) * | 2018-02-02 | 2019-08-08 | Aytu Bioscience, Inc. | Procedes de therapie a la testosterone |
| WO2019175290A1 (fr) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis ou compositions dérivées du cannabis pour favoriser l'arrêt de la dépendance chimique |
| CN108771622B (zh) * | 2018-07-11 | 2022-01-07 | 尹振图 | 一种自闭式针形滴嘴及眼药水瓶 |
| WO2020084548A1 (fr) | 2018-10-26 | 2020-04-30 | Viramal Limited | Composition de gel mucoadhésif |
| EP3659583B1 (fr) | 2018-11-30 | 2023-06-07 | Viramal Limited | Procédé de préparation d'un agent coagulant, agent coagulant ainsi obtenu et utilisation de cet agent coagulant |
| CN113365635A (zh) * | 2018-12-14 | 2021-09-07 | 阿克罗斯生物制药公司 | 睾酮的活性酯衍生物、组合物和其用途 |
| JP7508035B2 (ja) | 2020-03-10 | 2024-07-01 | オムロン株式会社 | 電子機器及び近接センサ |
| CN112121049B (zh) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用 |
| MX2023005822A (es) * | 2020-11-19 | 2023-05-31 | Acousia Therapeutics Gmbh | Composicion de gel no acuoso. |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| DE4214953C2 (de) | 1992-05-06 | 1995-05-18 | Arrowdean Ltd | Arzneimittel zur Erhöhung des Testosteronspiegels |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5576071A (en) | 1994-11-08 | 1996-11-19 | Micron Technology, Inc. | Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds |
| JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
| BR9814014B1 (pt) * | 1997-11-10 | 2014-10-07 | Strakan Int Ltd | Composição para aplicação tópica tendo propriedades de melhora da penetração |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| CA2463384A1 (fr) * | 2001-10-12 | 2003-04-17 | Cns, Incorporated | Gel nasal hydratant et applicateur |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| JP5619337B2 (ja) * | 2003-10-10 | 2014-11-05 | フェリング ビー．ブイ． | 皮膚残渣を最小限に抑えるための経皮的医薬製剤 |
| EP1530965B1 (fr) * | 2003-11-11 | 2006-03-08 | Mattern, Udo | Composition à liberation prolongée pour application nasale comprenant des hormones sexuelles |
| NZ555641A (en) * | 2004-12-09 | 2010-10-29 | Bayer Animal Health Gmbh | Stabilisation of glucocorticoid esters with acids |
| MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
| EP1790343A1 (fr) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme |
| CN101099742A (zh) * | 2006-07-06 | 2008-01-09 | 上海富海科申药业有限公司 | 能够减少皮肤刺激的睾酮凝胶制剂 |
| CN101600417B (zh) * | 2006-10-04 | 2012-05-30 | M&P专利股份公司 | 用于神经递质的经鼻施用的控制释放递送系统 |
| CA2623477C (fr) * | 2007-03-23 | 2011-05-31 | Robert E. Dudley | Compositions et methode pour le traitement de l'hypogonadisme chez les enfants |
| WO2009037813A1 (fr) * | 2007-09-20 | 2009-03-26 | Shiseido Company, Ltd. | Préparation pouvant être absorbée par voie transdermique |
| ES2539800T3 (es) * | 2007-11-13 | 2015-07-06 | Curadis Gmbh | Esteroides C-19 para usos terapéuticos |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| EP2709588B1 (fr) * | 2011-05-15 | 2021-08-25 | Acerus Biopharma Inc. | Gels nasaux de testostérone à libération prolongée, méthodes associées et systèmes applicateurs multi-doses pré-remplis destinés à une administration pernasale |
-
2012
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/fr active Active
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko active Application Filing
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Application Discontinuation
- 2012-05-15 CA CA2836398A patent/CA2836398C/fr active Active
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/fr not_active Withdrawn
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/fr active Active
- 2012-05-15 MX MX2020008599A patent/MX2020008599A/es unknown
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active IP Right Grant
- 2012-05-15 CA CA3034552A patent/CA3034552C/fr active Active
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh active Active
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Application Discontinuation
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko active Application Filing
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Application Discontinuation
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko active Application Filing
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Application Discontinuation
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/fr active Application Filing
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active IP Right Grant
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 PL PL12748245T patent/PL2714006T4/pl unknown
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/fr active Application Filing
- 2012-05-15 CA CA2836405A patent/CA2836405C/fr active Active
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
-
2013
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-11-15 MX MX2019003340A patent/MX2019003340A/es active IP Right Grant
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
-
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
-
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
-
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
-
2024
- 2024-08-23 AU AU2024216312A patent/AU2024216312A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020267162B2 (en) | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration | |
| US20160113946A1 (en) | Controlled release topical testosterone formulations and methods | |
| US20240316063A1 (en) | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | |
| US20150290217A1 (en) | Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170515 |